Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan [online]. American Medical Association. Dostupné online.
clinicaltrials.gov
A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography [online]. Dostupné online.
doi.org
dx.doi.org
Nerissa Viola-Villegas; Robert P. Doyle. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N′,N",N′"-tetraacetic acid (H4DOTA): Structural overview and analyses on structure–stability relationships. Coordination Chemistry Reviews. 2009, s. 1906. DOI10.1016/j.ccr.2009.03.013.
Min K. Moi; Claude F. Meares; Sally J. DeNardo. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid and study of its yttrium(III) complex. Journal of the American Chemical Society. 1988, s. 6266–6267. DOI10.1021/ja00226a063. PMID22148823.
W. A. P. Breeman; E. De Blois; H. Sze Chan; M. Konijnenberg; D. J. Kwekkeboom; E. P. Krenning. 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives. Seminars in Nuclear Medicine. 2011, s. 314–321. DOI10.1053/j.semnuclmed.2011.02.001. PMID21624565.
R. J. Domingo; R. M. Reilly. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Nuclear Medicine Communications. 2000, s. 89–96. DOI10.1097/00006231-200001000-00015. PMID10717908.
S. Knör; A. Modlinger; T. Poethko; M. Schottelius; H. J. Wester; H. Kessler. Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chemistry: A European Journal. 2007, s. 6082–6090. DOI10.1002/chem.200700231. PMID17503419.
nih.gov
ncbi.nlm.nih.gov
Min K. Moi; Claude F. Meares; Sally J. DeNardo. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid and study of its yttrium(III) complex. Journal of the American Chemical Society. 1988, s. 6266–6267. DOI10.1021/ja00226a063. PMID22148823.
W. A. P. Breeman; E. De Blois; H. Sze Chan; M. Konijnenberg; D. J. Kwekkeboom; E. P. Krenning. 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives. Seminars in Nuclear Medicine. 2011, s. 314–321. DOI10.1053/j.semnuclmed.2011.02.001. PMID21624565.
R. J. Domingo; R. M. Reilly. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Nuclear Medicine Communications. 2000, s. 89–96. DOI10.1097/00006231-200001000-00015. PMID10717908.
S. Knör; A. Modlinger; T. Poethko; M. Schottelius; H. J. Wester; H. Kessler. Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chemistry: A European Journal. 2007, s. 6082–6090. DOI10.1002/chem.200700231. PMID17503419.
